Summary
GlobalData, the industry analysis specialist, has released its new report, “Epilepsy – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Epilepsy market. The report identifies the key trends shaping and driving the global Epilepsy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Epilepsy sector.
Epilepsy Therapeutics – Pipeline Assessment and Market Forecasts to 2017
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates the global epilepsy market to be worth $8.7 billion in 2009, and is forecast to register a modest growth of 0.4% annually to reach $9 billion by 2017. The major factor to stagnate the growth is generic erosion of leading second generation antiepileptic drugs following patent expiry in 2010 and 2013. The market is forecasted to register a decline owing to competition from generics which is predicted to increase over the next two years. Increasing penetration and availability of generics continue to contribute to the barrier to entry for prospective players. The major drivers in the market are expected to be those featuring more convenient dosing with the launch of extended release formulation and a purported improved safety profile of drugs such as eslicarbazepine, (Sepracor), E2007 (Eisai); Rikelta (brivaracetam, UCB), which are expected to be launched in the market in few years. Second generation epileptic drugs such as levetiracetam and Vimpat are expected to drive the value of epileptic market.
Scope
The report provides information on the key drivers and challenges of the Epilepsy market. Its scope includes:
- Annualized global Epilepsy market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Ion Channel Inhibitor, GABA Modulators, Acetylcholine Agonist, Sigma 1 receptor agonist, Caspase-1 Inhibitor, Potassium Channel Opener, AMPA receptor antagonist, and Selective serotonin reuptake inhibitor
- Analysis of the current and future competition in the global Epilepsy market. Key market players covered are UCB, Eisai, Supernus Pharma, Lundbeck, GSK, Johnson & Johnson, Upsher-Smith Labs, King Pharma, Nobelpharma, CyDex Pharma, and Sepracor Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Epilepsy therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Epilepsy market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Epilepsy market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Epilepsy market landscape? – Identify, understand and capitalize.
